PPV 06
Alternative Names: Anti-IL-6 vaccine - Peptinov; PPV-06Latest Information Update: 30 Sep 2024
At a glance
- Originator Peptinov
- Class Anti-inflammatories; Antirheumatics; Peptide vaccines
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Osteoarthritis
- No development reported Multiple sclerosis
Most Recent Events
- 20 Sep 2024 Peptinov SAS plans to initiate a phase II trial for Osteoarthritis in France (SC) (NCT06605963)
- 13 Jun 2024 PPV 06 is still in Phase-I clinical trials for Osteoarthritis in France (SC) (NCT04447898) (Peptinov pipeline, June 2024)
- 12 Jun 2024 Immunogenecity and adverse events data from a phase I trial in Osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)